- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07942727
The Effect of Smoking on Salivary and Serum Lipidomic Profiles in Patients With Periodontitis
This observational study aims to investigate how smoking and periodontal health affect lipid profiles in saliva and blood serum. Periodontitis is a chronic inflammatory disease that affects the tissues supporting the teeth, while smoking is an important risk factor for periodontal disease.
The study will include 56 adults divided into four groups according to their periodontal health and smoking status: non-smokers with periodontitis, smokers with periodontitis, periodontally healthy non-smokers, and periodontally healthy smokers.
Saliva and blood samples will be collected from each participant. Lipid profiles will be analyzed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS). The study will examine the individual and combined associations of periodontitis and smoking with lipid profiles and explore the relationship between lipid patterns in saliva and serum.
The findings may help identify lipid-related changes associated with periodontal disease and smoking and improve our understanding of their effects on oral and systemic health.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Periodontitis is a chronic inflammatory disease characterized by the destruction of tooth-supporting tissues. Smoking is a major modifiable risk factor that influences periodontal inflammation, host immune responses, and disease progression. Both periodontitis and smoking may alter lipid metabolism and contribute to oxidative stress and inflammatory processes.
Lipidomics provides a comprehensive approach to investigating lipid species and metabolic alterations associated with disease. Saliva is a non-invasive biological fluid that may reflect both local oral conditions and systemic biological processes. Comparing salivary and serum lipidomic profiles may provide further insight into the metabolic changes associated with periodontal disease and smoking.
This observational, cross-sectional study will enroll 56 adults aged 18-65 years. Participants will be categorized into four groups based on periodontal status and smoking habits: periodontitis with smoking, periodontitis without smoking, periodontal health with smoking, and periodontal health without smoking.
Periodontal status will be determined through clinical periodontal examination. Saliva and blood samples will be obtained from the same participants, and untargeted lipidomic profiling will be performed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS).
The study will assess the associations of periodontal status and smoking with salivary and serum lipidomic profiles, including their potential interaction. Relationships between lipidomic patterns in the two biological fluids will also be investigated.
This study is expected to contribute to a better understanding of lipid-related biological alterations associated with periodontitis and smoking and may support future research into potential biomarkers of periodontal disease.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Nihan Akdoğan, DDS, PhD
- Telefonnummer: +905304070848
- E-mail: nihanakdogan@yahoo.com.tr
Undersøgelse Kontakt Backup
- Navn: Oğuzhan Durmaz, PhD
- Telefonnummer: +905369551469
- E-mail: durmazogz@gmail.com
Studiesteder
-
-
Ankara
-
Ankara, Ankara, Tyrkiet (Türkiye), 06560
- Rekruttering
- Ankara University Faculty of Dentistry
-
Kontakt:
- Nihan Akdoğan, DDS, PhD
- Telefonnummer: +905304070848
- E-mail: nihanakdogan@yahoo.com.tr
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
The study population will consist of 56 adults aged 18-65 years, categorized into four groups according to periodontal status and cigarette smoking: (1) patients with periodontitis who smoke, (2) patients with periodontitis who do not smoke, (3) periodontally healthy individuals who smoke, and (4) periodontally healthy individuals who do not smoke. Participants will be evaluated through clinical periodontal examinations, and saliva and serum samples will be collected for lipidomic profiling. All participants must meet the predefined eligibility criteria.
Beskrivelse
Inclusion Criteria:
Individuals aged 18 years or older. Individuals who do not use orthodontic appliances Women who are not pregnant or breastfeeding. Individuals without systemic diseases that may affect periodontal health. Individuals who have not used anti-inflammatory and/or antimicrobial medications within the past 6 months.
Individuals who have not received periodontal treatment within the past year.
Exclusion Criteria:
Individuals younger than 18 years. Individuals older than 65 years. Pregnant or breastfeeding women. Individuals who have used anti-inflammatory and/or antimicrobial medications within the past 6 months.
Individuals who have received periodontal treatment within the past year. Individuals with psychiatric disorders. Individuals with any oral infection. Individuals with alcohol dependence. Individuals with active infectious diseases (acute hepatitis, AIDS, or tuberculosis), cancer, or any systemic disease that may affect periodontal tissues.
Individuals receiving medications known to affect periodontal tissues, including phenytoin, cyclosporine A, or calcium channel blockers.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: CROSS_SECTIONAL
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Periodontitis Smokers
Adult participants diagnosed with periodontitis who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontitis Non-Smokers
Adult participants diagnosed with periodontitis who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontally Healthy Smokers
Adult participants with clinically healthy periodontal tissues who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontally Healthy Non-Smokers
Adult participants with clinically healthy periodontal tissues who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Salivary Lipidomic Profile
Tidsramme: At baseline (single sample collection)
|
Salivary lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status. |
At baseline (single sample collection)
|
|
Serum Lipidomic Profile
Tidsramme: At baseline (single sample collection)
|
Serum lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status. |
At baseline (single sample collection)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Probing Pocket Depth (PPD)
Tidsramme: At baseline (single clinical examination)
|
Probing pocket depth (PPD) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean PPD values will be calculated to characterize periodontal status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Attachment Loss (AL)
Tidsramme: At baseline (single clinical examination)
|
Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean AL values will be calculated to characterize periodontal tissue destruction, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Bleeding on Probing (BOP)
Tidsramme: At baseline (single clinical examination)
|
Bleeding on probing (BOP) will be assessed at six sites per tooth. The percentage of sites exhibiting bleeding will be calculated to characterize gingival inflammation, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Plaque Index (PI)
Tidsramme: At baseline (single clinical examination)
|
Plaque index (PI) will be assessed to quantify dental plaque accumulation. Individual plaque index scores will be calculated according to the study protocol to characterize oral hygiene status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Periodontale sygdomme
- Mundsygdomme
- Stomatognatiske sygdomme
- Opførsel
- Tobaksrygning
- Brug af tobak
- Paradentose
- Rygning
- Cigaretrygning
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Aminosyrer, peptider og proteiner
- Proteiner
- Undersøgelsesteknikker
- Epidemiologiske metoder
- Terapeutik
- Biologiske faktorer
- Dataindsamling
- Evalueringsmekanismer til sundhedsvæsenet
- Sundhedskvalitet
- Folkesundhed
- Miljø og folkesundhed
- Adfærdskontrol
- Immobilisering
- Bakterielle proteiner
- Sundhedsundersøgelser
- Undersøgelser og spørgeskemaer
- Tandlæge
- Antigener
- Dental Sundhedsundersøgelser
- Public Health Dentistry
- Antigener, bakteriel
- Vægte og foranstaltninger
- Tilbageholdenhed, fysisk
- Tuberculin
- Tandplakindeks
- short-wavelength opsin
Andre undersøgelses-id-numre
- 27/2
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data (IPD) will not be shared with other researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form through scientific publications without disclosing identifiable participant information.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .